To determine the effects of surgical portal decompression in Budd-Chiari syndrome (BCS) on survival, quality of life, shunt patency, liver function, portal hemodynamics, and hepatic morphology during periods ranging from 3.5 to 27 years.
Summary Background Data
Experiments in the authors' laboratory showed that surgical portal decompression reversed the deleterious effects of BCS on the liver. This study was aimed at determining whether similar benefit could be obtained in patients with BCS.
Methods
From 1972 to 1999, the authors conducted prospective studies of the treatment of 60 patients with BCS who were divided into three groups: the first had occlusion confined to the hepatic veins treated by direct side-to-side portacaval shunt (SSPCS); the second had occlusion involving the inferior vena cava (IVC) treated by a portal decompressive procedure that bypassed the obstructed IVC; and the third group, who had advanced cirrhosis and hepatic decompensation and were referred too late for treatment by portal decompression, required orthotopic liver transplantation.
Results
In the 32 patients with BCS resulting from hepatic vein occlusion alone, SSPCS had a surgical death rate of 3%, and 94% of the patients were alive 3.5 to 27 years after surgery. All 31 survivors remained free of ascites and almost all had normal liver function. No patient with a patent shunt had encephalopathy. The SSPCS remained patent in all but one patient. Liver biopsies showed no evidence of congestion or necrosis, and 48% of the biopsies were diagnosed as normal.
Mesoatrial shunt was performed in eight patients with BCS caused by IVC thrombosis. All patients survived surgery, but five subsequently developed thrombosis of the synthetic graft and died. Because of the poor results, mesoatrial shunt was abandoned. Instead, a high-flow combination shunt was introduced, consisting of SSPCS combined with a cavoatrial shunt (CAS) through a Gore-Tex graft. There were no surgical or long-term deaths among 10 patients who underwent combined SSPCS and CAS, and the shunts functioned effectively during 4 to 16 years of follow-up.
Ten patients with advanced cirrhosis were referred too late to benefit from surgical portal decompression, and they were approved and listed for orthotopic liver transplantation. Three patients died of liver failure while awaiting a transplant, and four patients died after the transplant. The 1-and 5-year survival rates were 40% and 30%, respectively.
Conclusions
SSPCS in BCS with hepatic vein occlusion alone results in reversal of liver damage, correction of hemodynamic disturbances, prolonged survival, and good quality of life when performed early in the course of BCS. Similarly good results are obtained with combined SSPCS and CAS in patients with BCS resulting from IVC occlusion. In contrast, mesoatrial shunt has been discontinued in the authors' program because of an unacceptable incidence of graft thrombosis and death. In patients with advanced cirrhosis from long-standing, untreated BCS, orthotopic liver transplantation is the only hope of relief and results in the salvage of some patients. The key to long survival in BCS is prompt diagnosis and treatment by portal decompression.
In 1970 we undertook an experimental evaluation in animals of the treatment of Budd-Chiari syndrome (BCS) by side-to-side portacaval shunt (SSPCS). In 1972, based on the results of our laboratory experiments, we began to use SSPCS to treat patients with BCS. In April 1978, at the annual meeting of the American Surgical Association, we reported our experimental findings and the results of what was then the largest clinical experience to date with the use of SSPCS in the therapy of BCS. 1 In the 27 years from 1972 to 1999, we conducted prospective studies of the treatment of 60 patients with BCS. This report includes the results of long-term follow-up studies of survival, quality of life, shunt patency, liver function, portal hemodynamics, and liver biopsy during periods of 3.5 to 27 years.
METHODS

Patients
On the basis of the duration of BCS and the site of hepatic outflow obstruction, the 60 patients in our series were divided into three groups. Group 1 (n ϭ 32) patients had occlusion confined to the hepatic veins, and they were treated by direct SSPCS. Group 2 (n ϭ 18) patients had occlusion involving the inferior vena cava (IVC) as well as the hepatic veins, and they were treated by a portal decompressive procedure that bypassed the obstructed IVC. Group 3 (n ϭ 10) patients had advanced cirrhosis and hepatic decompensation and were referred too late for treatment by portal decompression; they required liver transplantation. The patients were treated according to a well-defined protocol. Data were collected on-line and recorded on standard data forms for analysis. The presumed causes of BCS were polycythemia rubra vera in 15 patients, use of oral contraceptives in 15, Behçet disease in 5, protein C deficiency in 2, antithrombin III deficiency in 2, paroxysmal nocturnal hemoglobinuria in 1, and the postpartum state in 1. The cause was unknown in 19 patients (32%).
Diagnostic Studies
An extensive hematologic workup was performed that included the usual measurements of blood coagulation as well as plasma levels of protein C, protein S, plasminogen, antithrombin III, and heparin cofactor II; blood cell counts, measurement of total erythrocyte volume, erythroid colony cultures, and bone marrow biopsy; detection of lupus anticoagulant by antiphospholipid antibody assay; hemoglobin electrophoresis; acid hemolysis and sucrose tests for paroxysmal nocturnal hemoglobinuria; and determinations of activated protein C resistance and factor V Leiden mutation.
All patients underwent angiography of the IVC and hepatic veins with pressure measurements, indirect portography after injection of contrast in the superior mesenteric, celiac, and splenic arteries, measurement of wedge hepatic vein pressure, percutaneous needle liver biopsy, and a battery of liver function tests. Most patients had Doppler duplex ultrasonography and computed tomography of the abdomen. The diagnosis of BCS was based on angiographic demonstration of occlusion of the hepatic veins or IVC, and a histologic liver biopsy finding of intense sinusoidal congestion. All 60 patients had these findings. In addition, attention was directed to determining the feasibility of performing a direct SSPCS, which requires a patent portal vein and IVC, and a substantial gradient between wedge hepatic vein pressure and IVC pressure.
Portal Decompression Operations
Direct SSPCS, combined SSPCS and cavoatrial shunt (CAS), 2, 3 and mesoatrial shunt 4 were performed by the techniques we have described in detail previously. Before and after performance of the shunts, pressures were measured in the portal vein and IVC by direct needle puncture using a saline manometer positioned at the level of the IVC. In patients with IVC obstruction, pressures were also measured in the synthetic grafts and the right atrium. A large wedge liver biopsy was obtained from every patient. The volume of ascites was measured. All patient with a hematologic disorder received anticoagulation after surgery with heparin and were discharged from the hospital receiving permanent anticoagulation therapy with warfarin.
Follow-Up
Patients were observed in the portal hypertension clinic monthly for the first postoperative year and every 3 months thereafter. At each visit, clinical status was determined and measurements were made of liver function, renal function, and fluid and electrolyte balance. The presence of portasystemic encephalopathy was assessed by using four of the five tests described by Conn and Lieberthal (excluding electroencephalography) to calculate a portasystemic encephalopathy index. 5 Patency of the portasystemic shunts and grafts from the portal vein or IVC to the atrium was determined every year or two by duplex Doppler ultrasonography, abdominal angiography with pressure measurements, or both. Percutaneous needle liver biopsy was performed every year or two. No patient was lost to follow-up.
RESULTS
Patient Characteristics
Ages of the patients ranged from 19 to 45 years (mean 29.7), a young adult population. Were it not for BCS, their life expectancy would have been long. Thirty-two were men and 28 were women. Of the 60 patients, 10 were referred to us with advanced cirrhosis as a result of prolonged hepatic outflow obstruction and were not candidates for portal decompression surgery. The other 50 patients were referred a mean of 13.7 weeks after the onset of BCS (range 4 -78). Forty-six of the 50 patients (92%) were referred less than 18 weeks after the onset of symptoms, relatively early in the course of BCS. The remaining four patients underwent surgery 19, 21, 25, and 78 weeks after the onset of symptoms. Table 1 shows the frequency of symptoms and signs in the 60 patients with BCS, 41 of whom had hepatic vein occlusion alone and 19 of whom had occlusion of both the IVC and hepatic veins. The only difference between the two groups-and it is an important one-was the absence of lower extremity edema in the group without IVC thrombosis, and the high incidence of edema from feet to thighs that resulted from IVC occlusion. Percutaneous needle liver biopsy was performed before surgery in 57 of the 60 patients, and open wedge liver biopsy was performed in all patients who underwent surgery. All patients had the spectacular findings of intense centrilobular sinusoidal congestion with centrilobular hepatocellular loss and necrosis. Other than BCS, the only common conditions that cause severe hepatic congestion are right-sided heart failure and constrictive pericarditis. Both of these cardiac disorders can be easily eliminated from consideration by appropriate studies. Of the 50 patients in our series who were referred early enough to undergo surgical portal decompression, 31 (62%) had mild to severe fibrosis of the liver at an early point in their illness, depending on the duration of hepatic outflow obstruction. Three patients whose symptoms of BCS existed for 4 to 18 months before referral had cirrhosis on liver biopsy. All 10 patients who were considered candidates for liver transplantation had advanced cirrhosis.
Diagnostic Studies
In recent years, all of our patients with BCS have undergone duplex Doppler ultrasonography and computed tomography of the abdomen, often as initial screening procedures for suspected BCS. Of our 60 patients, 45 underwent ultrasonography and 47 underwent computed tomography. These studies demonstrated occlusion of the hepatic veins, patency or occlusion of the IVC, and patency of the portal vein. They served as a valuable baseline for postoperative follow-up evaluation. However, for the definitive diagnosis of BCS and the decision regarding surgical portal decompression, angiography is essential.
Results of liver function tests are shown in Table 2 . They were abnormal in all 60 patients with BCS. The biochemical abnormalities are not specific for BCS, but they clearly indicate significant hepatic dysfunction and are an important part of the diagnostic workup.
Barium contrast upper gastrointestinal radiographs were obtained in 53 patients with BCS. Esophageal varices were Table 3 summarizes important findings at surgery and the results of intraoperative pressure measurements in the 50 patients who underwent surgical portal decompression. All patients had marked ascites, congestive hepatomegaly, splenomegaly, portal hypertension, and extensive portasystemic collateral veins. In the 32 patients with thrombosis confined to the hepatic veins, portal pressure was substantially higher than IVC pressure, so that a direct SSPCS was feasible. SSPCS reduced the mean portal vein/IVC pressure gradient from 243 mm saline to 4.5 mm. The postshunt pressure gradient was 40 mm saline or less in every patient. In contrast, in the 18 patients with IVC occlusion as well as hepatic vein occlusion, the mean portal vein/IVC pressure gradient was only 14 mm saline because the high pressure in the obstructed IVC was similar to the high portal pressure. However, all 18 patients had a large pressure gradient between the portal vein and right atrium, averaging 202 mm saline.
Findings at Surgery
A wedge liver biopsy obtained at surgery showed intense centrilobular congestion and marked centrilobular cell loss and necrosis in all but one patient. Thirty-one of the 50 patients had hepatic fibrosis: mild or moderate in 27 and severe in 4 patients, 3 of whom had cirrhosis. Tables 4 and 5 summarize the long-term results of SSPCS in the 32 patients with hepatic vein occlusion alone, without obstruction of the IVC. There was one surgical death (3%). The 31 survivors of SSPCS were followed up for 3.5 to 27 years (mean 13.6); all but five were followed up for more than 5 years. There was one long-term death, a patient with Behçet disease who was cured of ascites but died of diffuse vasculitis causing hemorrhagic infarction of the colon 2 years after surgery. The other 30 patients were alive at the time of writing for an overall survival rate of 94%. All survivors remained free of ascites without requiring diuretic therapy. Results of periodic liver function tests were consistently normal, except in the three patients who already had cirrhosis when they were referred to us. None of the patients had portasystemic encephalopathy, undoubtedly because they had good hepatic function. Hepatosplenomegaly disappeared in all patients. Except for the patient who died of Behçet disease, all survivors were gainfully employed or engaged in full-time housekeeping. Twenty-nine of the 30 current survivors (97%) were leading productive lives of good quality.
Results of SSPCS for Hepatic Vein Occlusion
Liver biopsies and angiographic studies were performed periodically for up to 27 years after SSPCS in the 31 survivors. Cirrhosis persisted in the three patients who already had cirrhosis by the time of the shunt operation. In 97% of the survivors, there was no longer any evidence of hepatic congestion or necrosis in the follow-up biopsies. Mild to moderate fibrosis was found in 42% of the patients, but 48% had liver biopsies that were diagnosed as normal. Angiography demonstrated patency of the SSPCS and IVC, and pressure measurements showed a wide-open anastomosis with a gradient that ranged from 0 to 41 mm saline and averaged only 7 mm across the shunt. The hepatic veins did not recanalize.
Two patients with polycythemia rubra vera developed thrombosis of the SSPCS 1 week and 3 months after sur- gery. Both patients underwent immediate surgery, the shunt was taken down, fresh thrombus was removed from the portal vein, and the portacaval anastomosis was reconstructed with an H graft of autologous internal jugular vein. Subsequently, both patients received anticoagulant therapy with warfarin. One patient remained well for 19 years since revision of the shunt. The other patient developed recurrent shunt thrombosis and required liver transplantation; he was well 9.5 years after transplantation. Permanent anticoagulant therapy is now our policy for all patients with a known coagulopathy.
Results of Portal Decompression for IVC Occlusion
Mesoatrial Shunt
Mesoatrial shunt was performed in eight patients with BCS caused by thrombosis of both the IVC and hepatic veins. A 16-mm ring-reinforced Gore-Tex prosthesis was used. The results are shown in Tables 3, 4 , and 5. Mesoatrial shunt reduced the mean gradient between the portal vein and right atrium from 211 to 78 mm saline. All patients survived surgery and left the hospital alive. However, five of the eight (63%) subsequently developed thrombosis of the graft and died of liver failure. Three of the deaths occurred during the first postoperative year, one occurred in the second year, and one occurred in the fifth year. All five patients developed recurrence of ascites, and three developed portasystemic encephalopathy as their hepatic function deteriorated. The etiologies of BCS in the five patients whose mesoatrial shunt failed were similar to those found in the long-term survivors of portal decompression. The patients whose mesoatrial shunt failed were clearly not a higher-risk group. They died because their mesoatrial shunt thrombosed 1 to 5 years after insertion.
The three long-term survivors of mesoatrial shunt (38%) were followed up for 19, 17, and 17 years. Angiography demonstrated patency of their grafts. They were free of ascites, had normal liver function, and did not require diuretics. Two of the three were gainfully employed. Serial liver biopsies showed residual congestion in one patient and moderate fibrosis in two. In one patient, the liver appeared normal.
Combined SSPCS and CAS
The high thrombosis rate of the mesoatrial shunt may be due to the fact that it is a relatively low-flow synthetic graft placed in the venous system. Further, it does not decompress the obstructed IVC. To overcome these shortcomings, we worked in the experimental laboratory to devise a surgical procedure for this form of BCS consisting of combined SSPCS and CAS through a Gore-Tex graft. 3 This combined shunt was aimed at decompressing the hypertensive IVC and shunting the entire systemic venous flow from the lower two thirds of the body, as well as the entire portal venous flow, through the graft (Fig. 1) .
We treated 10 seriously ill patients with BCS caused by IVC thrombosis with combined SSPCS and CAS. The results are summarized in Tables 3, 4 , and 5. The mean gradient between the portal vein and right atrium was reduced from 195 to 22 mm saline. All 10 patients survived the combined shunt procedure and were alive as of this writing, 4 to 16 years after surgery. Mean follow-up was 9 
Orthotopic Liver Transplantation
Orthotopic liver transplantation (OLT) has been useful in advanced, decompensated liver disease when it is too late to use portal decompression procedures. The indications for OLT that we have adhered to are:
• Cirrhosis with progressive liver failure that has reached the point of permitting a reasonable prediction that the patient will die within a year
• Failure of SSPCS, usually because of thrombosis, with persistence or recurrence of symptoms and signs of BCS
• Unshuntable portal hypertension resulting from thrombosis of the portal vein, splenic vein, and much of the superior mesenteric vein, a rare indication that applies if patent blood vessels are available to vascularize the liver allograft
• Acute fulminant hepatic failure, a rare indication.
Ten patients were approved and listed for OLT. Their characteristics are shown in Table 6 . In 8 of the 10 patients, an underlying thrombogenic hematologic disorder was identified. The time lapse from the clinical onset of BCS to referral for OLT ranged from 11 to 17 months (average 14.6), much longer than in our patients who were treated by SSPCS. Clearly, these patients had a chronic form of BCS. The indication for OLT was cirrhosis with progressive liver failure in nine patients whose severe hepatic decompensation precluded consideration of SSPCS, and thrombosis of SSPCS with recurrence of clinical manifestations of BCS in one. In nine patients thrombosis was confined to the hepatic veins, and in one patient both the hepatic veins and suprahepatic IVC were occluded. All but one patient, the one with an occluded portacaval shunt, had a patent portal vein. All patients had massive ascites, jaundice, severe muscle wasting, hepatomegaly, splenomegaly, and dilated collateral veins on the abdominal wall. Encephalopathy had occurred in 40%, and one or more episodes of bleeding varices had occurred in 60%. All of them had cirrhosis on preoperative liver biopsy and in the recipient liver removed at OLT. Clearly, this was a group with advanced, decompensated liver disease. All of them were Child class C, determined by the quantitative scoring method of Campbell et al. 6 Liver function test results were highly abnormal and reflected serious hepatic failure. Serum bilirubin levels were substantially elevated, and serum albumin levels were markedly depressed in every patient. Prothrombin activity was invariably low, resulting in a mean international normalized ratio of 1.9. Table 7 shows the survival rate of the 10 patients who were approved and listed for OLT. Three patients died of liver failure while awaiting OLT during periods of 4 to 10 months. Two patients died during the immediate period after OLT, one of relentless graft rejection and one of sepsis with multisystem organ failure. A third patient died 9 months after surgery of liver failure, and a fourth patient died of chronic graft rejection 18 months after surgery. No patients died after the second year. The 1-and 5-year survival rates were 40% and 30%, respectively.
The three long-term survivors of OLT were followed up for more than 5 years and had a life of good quality. They were working full-time. There was no recurrence of BCS. All survivors were given anticoagulant therapy after surgery and take lifelong maintenance warfarin sodium. 
DISCUSSION
All forms of BCS produce serious hemodynamic consequences and severe liver damage from intense centrilobular congestion of the liver, with ischemia, pressure necrosis, and loss of parenchymal cells in the center of the liver lobule. As we and others 7 have observed, cirrhosis develops in a relatively short period, often in less than 6 months. Many patients die within months of the onset of signs and symptoms of BCS. Survivors of the acute phase of BCS usually develop cirrhosis and often die of liver failure or bleeding esophagogastric varices in a few years. Unless the liver is decompressed or replaced, few patients with the types of BCS usually encountered in North America survive more than a few years. [7] [8] [9] [10] Decompression of the liver by nonsurgical measures is rarely if ever feasible. Thrombolytic therapy with urokinase or streptokinase has been used in several patients in an attempt to dissolve the thrombi and restore hepatic venous outflow. 9 -16 The experience with thrombolytic therapy has been recorded in sketchy anecdotal reports involving short follow-up. Approximately one third of the patients were believed to have had a clinical response to treatment for periods ranging from 2 months to 1 year. Half of the patients died of BCS during the brief periods of observation. Pulmonary embolization developed in some patients during thrombolytic therapy; this is a potentially serious complication of this type of treatment. Anticoagulant therapy has been used widely in BCS to prevent propagation of the thrombi. 9, 10, 13, [17] [18] [19] [20] [21] [22] [23] Again, most reports of the effectiveness of this form of treatment have been anecdotal and lacking in long-term follow-up. There is no evidence that the use of either heparin or warfarin produces dissolution of established thrombosis. In BCS caused by hematologic disorders such as polycythemia rubra vera and paroxysmal nocturnal hemoglobinuria, dramatic responses to intravenous heparin therapy have been reported, although relapses have been common. 18, 20, 22 The prognosis of BCS with nonsurgical therapy is poor. In his large collective review in 1959, Parker 7 wrote, "The majority of cases have proved fatal and there is little evidence to suggest that recovery from occlusion of the major hepatic veins occurs once symptoms have been produced." Similarly, in 1975, Tavill et al 8 wrote, "The prognosis of the Budd-Chiari syndrome is almost uniformly bad." In 1982, Mitchell et al 9 stated in their review, "Spontaneous resolution of hepatic vein occlusion rarely if ever occurs. Conventional medical therapy does little to reverse the pathophysiology in patients with hepatic vein occlusion."
Our series is the single largest clinical experience reported to date involving the use of SSPCS in BCS confined to the hepatic veins. The results demonstrate the efficacy of SSPCS in relieving hepatic venous outflow obstruction. All 31 of our patients in whom thrombosis remained localized to the hepatic veins survived surgery and remained free of ascites for years without requiring diuretic therapy. The shunt remained permanently patent in all but one patient. All but three of the survivors underwent surgery early in the course of the disease before liver damage was irreversible, and in these patients hepatosplenomegaly disappeared and liver function returned rapidly to normal. The results of serial liver biopsies performed 3.5 to 27 years after surgery are particularly encouraging: they show that the shunt produced substantial and long-term reversal of the striking pathologic lesions of BCS. SSPCS appears to be the most effective treatment of BCS confined to the hepatic veins.
SSPCS is indicated only in patients with BCS who have a patent IVC and an IVC pressure that is substantially lower than wedge hepatic vein or portal pressure. Obstruction or occlusion of the IVC, manifested clinically by edema of the lower extremities and lower trunk and demonstrable by angiography and IVC pressure measurements, is a contraindication to SSPCS. It is not unusual for patients with BCS caused by hepatic vein occlusion alone to have an elevated pressure in the IVC as a result of caval compression by an enlarged, congested liver, massive ascites, or both. The absolute level of IVC pressure is not critical to the effectiveness of SSPCS as long as the portal pressure is substantially higher than caval pressure and the IVC is shown to be patent. Others have reported relief of BCS by in-continuity mesocaval shunt in patients with high IVC pressure but substantially higher portal pressure, demonstrating that it is possible to decompress the liver if there is a substantial differential between pressures in the portal vein and IVC. 24 In our long-term follow-up studies after SSPCS, we have observed that compression of the IVC disappears with relief of hepatic congestion, and caval pressure moves toward normal.
When BCS involves thrombosis or occlusion of the IVC, mesoatrial shunt has been used with short-term success, although there is a high incidence of thrombosis of the synthetic bypass graft. In our eight patients, thrombosis of the graft developed in five, and the 5-year survival rate was only 38%. Similarly, others have reported thrombosis of the 
* Causes of six deaths: rejection (25 days, 18 mo), n ϭ 2; sepsis (30 days), n ϭ 1; liver failure (9 mo), n ϭ 1; liver failure awaiting OLT (4 -10 mo), n ϭ 3. OLT, orthotopic liver transplantation.
mesoatrial shunt in 40% to 70% of patients, an event often followed by death. [25] [26] [27] [28] [29] [30] In a recent retrospective review of 19 patients with mesoatrial shunts, Slakey et al 30 reported a primary shunt patency rate of only 46% and a secondary patency rate of 69% after shunt revision.
Because of dissatisfaction with the results of mesoatrial shunt, we worked in the experimental laboratory to devise a shunting procedure aimed at decompressing the hypertensive IVC and shunting both the portal venous flow and the entire inferior vena caval flow to the right atrium. The combined procedure was found to be effective in relieving BCS in rats and was successful in 10 patients with BCS resulting from IVC occlusion during follow-up of 4 to 16 years. In our program, the combined shunt procedure has replaced mesoatrial shunt as the preferred treatment for BCS caused by IVC occlusion.
Orthotopic liver transplantation is indicated in patients with chronic BCS who have cirrhosis with progressive hepatic failure, and in patients who have undergone an unsuccessful portasystemic shunt. In approximately 176 patients with advanced liver disease resulting from BCS, OLT has produced an actuarial 5-year survival rate of 50% to 69%. [31] [32] [33] [34] [35] [36] [37] [38] In our experience with 10 patients approved for OLT, 3 died on the waiting list, and the 5-year survival rate was 30%. OLT and SSPCS are not competing forms of treatment. SSPCS is the appropriate treatment in the early and middle stages of BCS, when portal decompression will sustain life by reversing or stabilizing the liver disease. OLT is the appropriate treatment in the late stages of BCS, when the liver disease is no longer reversible and progressive hepatic decompensation cannot be stabilized. By and large, patients who are candidates for OLT should be in Child class C.
It has been suggested that OLT is preferable to SSPCS in the treatment of BCS because if SSPCS fails, the risk of performing subsequent OLT is increased. Also, it has been proposed that mesocaval shunt is preferable to SSPCS because it is advantageous to avoid dissection of the hepatic hilum should subsequent OLT be required. 39, 40 In our experience, patients with BCS treated by SSPCS infrequently require OLT. Of 42 patients with BCS whom we treated by SSPCS, only 1 subsequently required OLT (4%). Further, in our experience with more than 2,000 portacaval shunts in patients with cirrhosis, the long-term shunt patency rate was 99.8%. Also, at least eight recent studies have shown that a previous portasystemic shunt, regardless of type, had no influence on the outcome of OLT. [41] [42] [43] [44] [45] [46] [47] [48] Aboujaoude et al 48 emphasized that thrombosis of a portasystemic shunt may seriously compromise performance of OLT, so that longterm shunt patency should be the main factor that determines the type of shunt selected for the potential OLT candidate, a point that is especially important in patients with BCS. Direct portacaval shunt had a thrombosis rate of 0.2% or less in all of our studies, compared with occlusion rates of 24% to 53% for mesocaval interposition shunts using synthetic grafts reported in the literature. 49 -52 Mesocaval interposition shunts using autologous internal jugular vein grafts, used widely in France, have shown patency rates comparable to those of direct SSPCS. 24, 39, 53 Diagnosing BCS is neither complicated nor difficult. Once the diagnosis is made, there is no reason to delay surgical portal decompression. In acute BCS, nonsurgical treatment carries a high death rate in a population of young patients who usually have a benign underlying condition. Of the 60 patients in our series, 57 (95%) were younger than 35 years. When portal decompression is performed early in the course of BCS, liver damage and the hemodynamic disturbances are reversed. However, a delay in diagnosis or treatment results in irreversible liver damage. There is no rational basis for prolonged observation or for use of nonsurgical therapy, which has little chance of success. The key to long survival in BCS is prompt treatment by surgical portal decompression.
Discussion
DR. KAJ H. JOHANSEN (Seattle, Washington): In 1978, before this organization actually, you presented a small series of patients-I believe one of the first reasonable series of patients with BuddChiari syndrome-in whom it was demonstrated that portal decompression actually had a survival advantage. I am struck that in the subsequent 22 years, your series has expanded substantially. Is this due to simple referral by us, or, alternatively, is Budd-Chiari syndrome increasing in incidence? If the latter, could you speculate why?
Second, your serial liver biopsy studies demonstrate that if portal decompression is timely, there are indeed changes in the histopathologic morbidity associated with Budd-Chiari syndrome. What degree of cirrhosis and hepatocellular degeneration seen on serial liver biopsy would cause you to stay your hand, if you will, and refer the patient directly for liver transplantation? Is there indeed such a picture that would cause you to do that?
Finally, speaking as a vascular surgeon, I am loathe to avoid the issue of two separate types of catheter-directed adjunctive therapy. In the type of Budd-Chiari syndrome resulting from IVC occlu-sion, the type 2 indication you have described here, would therapy not be facilitated by the performance of an initial or concurrent stenting or angioplasty of the occluded vena cava either due to thrombosis or due to compression by a swollen segment 1 of the liver? In so doing, it would seem to me that if you did this-and we have had such an experience in one patient-you convert this second type of Budd-Chiari syndrome to the first type of BuddChiari syndrome, thereby facilitating a straightforward side-to-side portacaval shunt as the only operative therapy required.
Second, because a number of these patients are critically ill and are poor candidates for what is, even in your hands, a major operative intervention, what about initial performance of an angiographic portacaval shunt, a TIPS procedure, as a holding maneuver, then resuscitating the patient, getting the patient over the initial acute metabolic abnormalities of the acute Budd-Chiari syndrome, and then, with the inevitable failure of the TIPS graft some weeks or months down the road, performance of a semielective portacaval shunt? PRESENTER DR. MARSHALL J. ORLOFF (San Diego, California): Regarding the first question, the increasing incidence of BuddChiari syndrome, there is no question that there has been a marked increase in reported cases. The reason for that is speculative, but I think it is at least in part due to much improved diagnosis and awareness of the condition. In the literature there are now over 4,000 cases of BCS, so that is a true increase in reporting incidence.
Also, there is such widespread use of oral contraceptives in the United States and in the Western world, not so much in the East. In our series, the most common condition to cause Budd-Chiari syndrome has been the use of oral contraceptives. Such widespread use of birth-control pills may contribute to an increased incidence of BCS. Of course, this explanation is speculative.
Regarding referral of patients for liver transplantation rather than treating them by portacaval shunt, we have referred patients for transplantation only when they have been sent to us with advanced cirrhosis, proven by biopsy, and the usual manifestations of hepatic decompensation. All of these patients have been in Child class C. Regarding referral for liver transplantation after an effective portal decompression, we have not referred any patient, either on the basis of our serial liver biopsies or on the basis of their clinical course. The only patient we have referred for liver transplantation was one who had a thrombosed shunt, and that patient is alive now, some 9 1 ⁄2 years later. The reason referral for transplantation has been unnecessary except in the one patient with a thrombosed shunt is that the decompression of the liver really reverses, or at least stabilizes, the liver disease so it is not progressive. Therefore, I don't think there has been any indication on the basis of liver morphology to subsequently refer a patient for transplantation. It is rare after successful portal decompression for a patient to require subsequent therapy.
As to the question about doing an initial vena cava angioplasty in patients with BCS due to IVC occlusion, angioplasty has been tried with some frequency, over 200 patients, with generally poor results. The results often have been good initially, but ultimately there has been a high failure rate, despite repeated attempts to open up the IVC. One reason why there has been such a high death rate in BCS is that definitive treatment has been delayed by attempts at therapy that turn out to be unsuccessful. If one treats the patients early, the liver disease is completely reversible. In 48% of our patients, the liver architecture reverted to normal. But if one goes through a series of subpar treatments, the liver damage increases and increases, so that by the time the patient comes to definitive therapy, the patient already has cirrhosis. Therefore, I think a strategy that involves preliminary angioplasty is unwise. Now, the same holds true for TIPS, which has been tried in a number of these patients. As is true of TIPS in general, it does decompress the system and result in early improvement, but has a high thrombosis rate, all the more so in BCS because of the underlying hematologic thrombogenic disturbance. The failure rate in reported cases of TIPS for BCS has been greater than 50%. So, again, I do not believe that preliminary TIPS is a good strategy. I think the best strategy is to do what really works, and to do it early.
DR. RONALD W. BUSUTTIL (Los Angeles, California): Over the past 15 years, as you have mentioned, the surgical management of Budd-Chiari syndrome has been repeatedly shown to be better than medical therapy. However, I think we have all continued to wrestle with the optimal procedure for diagnosis. Given the fine nuances of the almost 23 different operations that have been described, that are in turn compounded by variations to the various clinical symptoms that Budd-Chiari syndrome presents with, it can be very problematic for the individual treating them.
Clearly, the earliest work in the literature has concentrated on using a side-to-side shunt as being the best treatment, as you have indicated. However, more recent reports, I believe, indicate that perhaps we ought to be looking at the pathophysiology of the disease over and above the hepatic vein occlusion we see. For instance, although medical treatment in the past has been uniformly deemed to be unsuccessful, there is now an emerging body of evidence to suggest that if you treat these patients early on-that is, before all three hepatic veins are occluded-that with angioplasty, with anticoagulation, and in many cases with hydroxyurea, to treat the hematologic disorders, that these patients can be maintained long-term without the need for shunting. I would like your comments on that.
Regarding your new technique, I am in complete agreement with the fact that the mesoatrial shunts really are not very effective. In fact, we have abandoned them. We have done several of the side-to-side portocavals in conjunction with a cavoatrial shunt, and I have three patients that are now long-term survivors as long as 8 to 10 years, and those have really worked very well. And we have not done the mesoatrials any longer.
Finally, I would like to comment just a moment about liver transplantation for this disease. We too agree that liver transplantation should be reserved for the patient who has decompensated liver disease. Specific indications include those that have a failed shunt, a thrombosed portal system, or fulminant hepatic failure. What surprises me is that you only have a 30% or 40% survival in the group of patients that underwent liver transplantation. We have transplanted over 30 of these patients with an 80% survival. And that leads me to a single question: Is it possible that you are shunting these patients a little bit too early, and that perhaps now, with newer diagnostic modalities, some of these patients can be treated medically, and reserve the shunt for those that have all three veins occluded and that do not have decompensated liver disease?
Finally, are you referring these patients perhaps too late for liver transplantation? I think your mean time for referral was a year and a half or so, if my memory serves me correctly. Perhaps if those patients had been referred a little bit earlier, the outcome would not have been as dismal as you reported. Surgical Treatment of Budd-Chiari Syndrome DR. ORLOFF: In response to Dr. Busuttil, it may be true that in patients who are seen early, before all of the major hepatic veins are occluded, it might be possible to prevent progression of the disease before it involves the entire hepatic outflow tract. In patients with polycythemia rubra vera, who made up 25% of our series, therapy with hydroxyurea has been very effective in controlling the disease. The problem is that we do not see patients early in the game. By the time they've been referred to us, they have had occlusion of all of the major hepatic veins and have all of the clinical manifestations of BCS. In a better world, surgeons would control the whole population of patients with BCS and thereby, would be able to dictate at what stage of disease the patients are seen. However, that is not the reality of patient referral in our experience. Thanks for your confirmation of the validity of our type of combined decompression for BCS due to IVC occlusion, and it is interesting you also were very disappointed in the mesoatrial shunt and have abandoned it.
Our liver transplant series doesn't represent what can be accomplished with liver transplantation. They were all patients who were referred to us an average of 14 1 ⁄2 months after the onset of BCS, when they had advanced cirrhosis, were in Child class C, and were already decompensated. In your reported series of BCS treated by liver transplantation, it is clear that you were operating on patients with liver disease that was less advanced than in our series. However, as I mentioned before, we do not control the time at which patients are referred to us. There were no patients in our series who were watched along by us until they decompensated, and then were referred to a transplantation program. Only one postshunt patient in our series, the one with a thrombosed shunt, required liver transplantation after the shunt.
The low survival rate of the patients referred for liver transplantation in part reflects deaths while waiting on the transplant listsomething that you know far better than I do. Three of our patients died while waiting because there were no livers available or allocated. That presents a problem in all diseases requiring liver transplantation. I have no doubt that in a large series of liver transplants for BCS one could achieve better survival rates than our patients experienced. But I would hope that we would be able to treat patients before they get to the stage of requiring liver transplantation.
